Bicara Therapeutics – Talk Bio

Actionable Insights Powered by AI

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

6 days ago talkbio0Tagged 2025, Alfa, Antibody Therapy, ASCO, Bicara Therapeutics, Cancer of Neck, Head, Keytruda, Overall Survival, PD-L1, tumor shrinkage

ASCO 2025; Bicara Therapeutics; ficerafusp alfa; head and neck cancer; PD-L1; overall survival; antibody therapy; Keytruda; tumor shrinkage

Biotech IPO Market Sees Rare Upsurge with Triple Listing Success

9 months ago talkbio0Tagged Bicara Therapeutics, Biosciences, biotech, Drug Industry, Flux, IPO, Market, MBX, Stock Surge, Tripleheader, Zenas BioPharma

Biotech IPO, Market Flux, Tripleheader, Bicara Therapeutics, Zenas BioPharma, MBX Biosciences, Stock Surge, Pharmaceutical Industry